Genomic studies have shown that the most relevant changes found in GBM specimens, compared to brain normal tissues, include genomic rearrangement with activating point mutations in EGFR, MET, and PDGFRA receptors, dysregulation of downstream PI3K- and AKT-dependent signaling pathways, loss of tumor suppressor CDKN2A, TP53, RB, PTEN and NF1, and mutations in the TERT promoter [72]. This evidence concerns the gene EGFR and glioblastoma.